Profile data is unavailable for this security.
About the company
Third Harmonic Bio, Inc. is a biopharmaceutical company. The Company is focused on advancing the next wave of medicine for inflammatory diseases through the development of novel, small-molecule inhibitors of KIT, a cell surface receptor that serves as the master regulator of mast cell function and survival. It is developing medicine for the treatment of inflammatory diseases, including dermal, respiratory, and gastrointestinal diseases. Mast cells are a part of the immune system, and dysfunctional mast cell activity has been implicated in the pathophysiology of a broad range of inflammatory disorders including urticaria, asthma and gastrointestinal disorders, among others. The Company is advancing its lead product candidate, THB335, for the treatment of multiple mast cell-driven inflammatory diseases of the skin, airway and gastrointestinal tract. THB335 is a potent, highly selective, oral small molecule KIT inhibitor with a promising preclinical product profile.
- Revenue in USD (TTM)0.00
- Net income in USD-29.60m
- Incorporated2019
- Employees31.00
- LocationThird Harmonic Bio Inc1700 Montgomery Street, Suite 210SAN FRANCISCO 94111United StatesUSA
- Phone+1 (209) 727-2457
- Fax+1 (302) 655-5049
- Websitehttps://thirdharmonicbio.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| C4 Therapeutics Inc | 20.04m | -126.07m | 472.01m | 145.00 | -- | 1.83 | -- | 23.56 | -2.37 | -2.37 | 0.3677 | 3.76 | 0.0504 | -- | 2.84 | 138,179.30 | -31.74 | -25.91 | -36.02 | -29.45 | -- | -- | -629.24 | -292.35 | -- | -- | 0.00 | -- | -33.25 | 1.40 | -3.37 | -- | -8.68 | -- |
| Voyager Therapeutics Inc | 119.04m | -3.04m | 474.86m | 162.00 | -- | 1.39 | 312.82 | 3.99 | -0.1812 | -0.1812 | 2.44 | 6.28 | 0.2954 | -- | 8.27 | 734,839.50 | -0.7554 | 0.6378 | -0.8534 | 0.8203 | -- | -- | -2.56 | 1.30 | -- | -- | 0.00 | 0.00 | 511.16 | 101.01 | 385.14 | -- | -5.43 | -- |
| Northwest Biotherapeutics Inc | 1.34m | -72.21m | 475.63m | 25.00 | -- | -- | -- | 356.01 | -0.0629 | -0.0629 | 0.0012 | -0.0447 | 0.0435 | -- | -- | 53,440.00 | -228.72 | -381.58 | -- | -- | -- | -- | -5,258.91 | -6,479.25 | -- | -10.49 | -- | -- | 14.80 | 36.21 | 38.71 | -- | 77.88 | -- |
| Absci Corp | 5.35m | -109.19m | 495.31m | 155.00 | -- | 2.06 | -- | 92.63 | -1.17 | -1.17 | 0.0569 | 2.12 | 0.0187 | -- | 7.82 | 34,496.77 | -38.26 | -- | -42.14 | -- | -- | -- | -2,042.01 | -- | -- | -107.74 | 0.0298 | -- | -0.5046 | -- | -5.40 | -- | -- | -- |
| Anavex Life Sciences Corp | 0.00 | -40.59m | 501.08m | 40.00 | -- | 3.67 | -- | -- | -0.4962 | -0.4962 | 0.00 | 1.61 | 0.00 | -- | -- | 0.00 | -26.73 | -40.04 | -28.98 | -43.97 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 0.9857 | -- | -- | -- |
| Fate Therapeutics Inc | 6.48m | -190.05m | 507.69m | 181.00 | -- | 1.19 | -- | 78.37 | -1.92 | -1.92 | 0.0653 | 3.74 | 0.0108 | -- | 0.9024 | 35,790.05 | -31.67 | -31.82 | -34.36 | -36.05 | -- | -- | -2,933.79 | -359.33 | -- | -- | 0.00 | -- | -34.03 | 68.05 | 42.88 | -- | 21.72 | -- |
| Compass Pathways PLC (ADR) | 0.00 | -129.44m | 510.12m | 186.00 | -- | 1.97 | -- | -- | -2.37 | -2.37 | 0.00 | 3.79 | 0.00 | -- | -- | 0.00 | -53.68 | -40.85 | -57.32 | -44.48 | -- | -- | -- | -- | -- | -43.34 | 0.1009 | -- | -- | -- | -29.46 | -- | -12.68 | -- |
| Third Harmonic Bio Inc | 0.00 | -29.60m | 511.87m | 31.00 | -- | 1.91 | -- | -- | -0.7475 | -0.7475 | 0.00 | 6.55 | 0.00 | -- | -- | 0.00 | -10.53 | -- | -10.70 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 12.32 | -- | -- | -- |
| Fulcrum Therapeutics Inc | 2.51m | -99.43m | 519.60m | 76.00 | -- | 2.43 | -- | 207.01 | -1.61 | -1.61 | 0.0406 | 3.44 | 0.0091 | -- | 2.14 | 33,026.32 | -35.91 | -50.55 | -37.62 | -55.91 | -- | -- | -3,961.20 | -1,189.10 | -- | -- | 0.00 | -- | -55.77 | -- | 11.41 | -- | -43.70 | -- |
| Heron Therapeutics Inc | 132.10m | -80.95m | 527.29m | 126.00 | -- | -- | -- | 3.99 | -0.6156 | -0.6156 | 0.9316 | -0.2245 | 0.6021 | 1.20 | 2.26 | 1,048,405.00 | -36.90 | -53.55 | -56.71 | -71.24 | 57.08 | 52.52 | -61.28 | -170.12 | 1.90 | -- | 1.29 | -- | 17.99 | 10.40 | 39.26 | -- | -29.97 | -- |
| Altimmune Inc | 410.00k | -92.77m | 531.06m | 59.00 | -- | 3.07 | -- | 1,295.26 | -1.59 | -1.59 | 0.007 | 2.44 | 0.0022 | -- | 1.47 | 6,949.15 | -49.42 | -39.62 | -53.14 | -42.58 | -- | -- | -22,626.10 | -1,811.89 | -- | -- | 0.00 | -- | 726.47 | -47.15 | -4.41 | -- | -45.92 | -- |
| Nkarta Inc | 0.00 | -116.20m | 533.44m | 150.00 | -- | 1.13 | -- | -- | -2.35 | -2.35 | 0.00 | 6.72 | 0.00 | -- | -- | 0.00 | -22.45 | -32.39 | -23.55 | -34.05 | -- | -- | -- | -372,519.20 | -- | -- | 0.00 | -- | -- | -- | -3.22 | -- | 106.05 | -- |
| Contineum Therapeutics Inc | 50.00m | 19.13m | 541.73m | 31.00 | 27.67 | -- | 27.99 | 10.83 | 0.7611 | 0.7611 | 1.99 | 4.66 | -- | -- | -- | 1,612,903.00 | -- | -- | -- | -- | -- | -- | 38.25 | -- | -- | -- | 0.00 | -- | -- | -- | 193.68 | -- | -- | -- |
| Y-mAbs Therapeutics Inc | 84.50m | -21.67m | 552.04m | 100.00 | -- | 5.56 | -- | 6.53 | -0.496 | -0.496 | 1.93 | 2.26 | 0.6481 | 1.31 | 4.30 | 844,990.00 | -16.62 | -44.23 | -19.95 | -50.45 | 86.53 | -- | -25.64 | -181.13 | 5.67 | -- | 0.00 | -- | 29.96 | -- | 77.58 | -- | -- | -- |
Data as of Jul 22 2024. Currency figures normalised to Third Harmonic Bio Inc's reporting currency: US Dollar USD
35.01%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| BVF Partners LPas of 31 Mar 2024 | 4.37m | 10.66% |
| EcoR1 Capital, LLCas of 31 Mar 2024 | 3.18m | 7.77% |
| RA Capital Management LPas of 31 Mar 2024 | 2.03m | 4.97% |
| Commodore Capital LPas of 31 Mar 2024 | 1.25m | 3.05% |
| BlackRock Fund Advisorsas of 31 Mar 2024 | 1.20m | 2.93% |
| The Vanguard Group, Inc.as of 31 Mar 2024 | 837.06k | 2.04% |
| JPMorgan Securities LLC (Investment Management)as of 31 Mar 2024 | 434.17k | 1.06% |
| Geode Capital Management LLCas of 31 Mar 2024 | 400.07k | 0.98% |
| SSgA Funds Management, Inc.as of 31 Mar 2024 | 380.39k | 0.93% |
| Millennium Management LLCas of 31 Mar 2024 | 255.29k | 0.62% |
More ▼
Data from 31 Mar 2024 - 31 Mar 2024Source: FactSet Research Systems Inc.
